Pfizer fell 2.47% to $23.72 in the latest trading session, even as the S&P 500, Dow and Nasdaq all finished higher. For holders of PFE, that means the stock lagged the broader tape on a day when the main benchmarks were moving the other way.
Pfizer and the 2.47% drop
6.61% is the size of Pfizer’s decline over the last month, a stretch that has left it behind the Medical sector, which gained 12.48% in the same period. The comparison is straightforward: Pfizer is trading under more pressure than the sector it sits in, and the gap is large enough to matter for anyone tracking relative strength rather than just the last print.
0.72%, 0.3% and 1.12% were the gains for the S&P 500, Dow and Nasdaq in the latest session. Pfizer moved against that backdrop, so the day was not a broad market washout; it was a company-specific underperformance inside a rising market.
August 4 earnings for PFE
August 4, 2026 is the next hard date in the story, when Pfizer is slated to reveal earnings. Zacks Consensus Estimates point to $0.68 per share, down 12.82% from the prior year, with revenue projected at $14.48 billion, a 1.2% decline.
$2.99 per share is the annual EPS target in the Zacks Consensus Estimates, alongside revenue of $61.85 billion. Those full-year figures imply declines of 7.14% for earnings and 1.17% for sales, so the upcoming report is arriving with expectations already set lower than last year’s run rate.
Valuation versus the Large Cap Pharmaceuticals industry
8.15 is Pfizer’s Forward P/E, well below the industry’s 16.26. That discount leaves the stock priced more cheaply than the Large Cap Pharmaceuticals industry inside the Medical sector, while the industry itself holds a Zacks Industry Rank of 107 and sits in the top 44% of over 250 industries.
0.03% is how much the Zacks Consensus EPS estimate moved lower over the last 30 days. If that path holds into August 4, the earnings release will matter less as a surprise event than as a test of whether Pfizer can narrow the gap between its share price, its sector and its own earnings outlook.
